Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of BI 1323495 with Itraconazole
NCT04011241Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2019
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BI 1323495 in Non-Cystic Fibrosis Bronchiectasis (NCFB) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area Under the Concentration-time Curve of BI 1323495 in Plasma Over the Time Interval From 0 to the Last Quantifiable Data Point up to 167 hours and Maximum Measured Concentration of BI 1323495 in Plasma up to 167 hours. Started Jul 2019; status: completed.
02
Drugs
BI 1323495
03
Conditions
Non-Cystic Fibrosis Bronchiectasis (NCFB)
Beyond the preview
Go deeper on NCT04011241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04011241.